Levocarnitine for asparaginase-induced hepatic injury: a multi-institutional case series and review of the literature

References

• Stock W, Douer D, DeAngelo DJ, et al. Prevention and management of asparaginase/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel. Leuk Lymphoma. 2011;52:2237–2253.
   PubMed Web of Science ®Google Scholar
• Aldoss I, Douer D, Behrendt CE, et al. Toxicity profile of repeated doses of PEG-asparaginase incorporated into a pediatric-type regimen for adult acute lymphoblastic leukemia. Eur J Haematol. 2016;96:375–380.
   PubMed Web of Science ®Google Scholar
• DeAngelo DJ, Stevenson KE, Dahlberg SE, et al. Long-term outcome of a pediatric-inspired regimen used for adults aged 18-50 years with newly diagnosed acute lymphoblastic leukemia. Leukemia. 2015;29:526–534.
   PubMed Web of Science ®Google Scholar
• Stock W, La M, Sanford B, et al. What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children’s Cancer Group and Cancer and Leukemia Group B studies. Blood. 2008;112:1646–1654.
   PubMed Web of Science ®Google Scholar
• Raetz EA, Salzer WL. Tolerability and efficacy of L-asparaginase therapy in pediatric patients with acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 2010;32:554–563.
   PubMed Web of Science ®Google Scholar
• Silverman LB, Gelber RD, Dalton VK, et al. Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. Blood. 2001;97:1211. 8.
   PubMed Web of Science ®Google Scholar
• Asselin B, Rizzari C. Asparaginase pharmacokinetics and implications of therapeutic drug monitoring. Leuk Lymphoma. 2015;56:2273–2280.
   PubMed Web of Science ®Google Scholar
• Alachkar H, Fulton N, Sanford B, et al. Expression and polymorphism (rs4880) of mitochondrial superoxide dismutase (SOD2) and asparaginase induced hepatotoxicity in adult patients with acute lymphoblastic leukemia. Pharmacogenomics J. 2017;17:274–279.
   PubMed Web of Science ®Google Scholar
• Hijiya N, van der Sluis IM. Asparaginase-associated toxicity in children with acute lymphoblastic leukemia. Leuk Lymphoma. 2016;57:748–757.
   PubMed Web of Science ®Google Scholar
• Place AE, Stevenson KE, Vrooman LM, et al. Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial. Lancet Oncol. 2015;16:1677–1690.
   PubMed Web of Science ®Google Scholar
• Ozdemir ZC, Turhan AB, Eren M, et al. Is N-acetylcysteine infusion an effective treatment option in L-asparaginase associated hepatotoxicity? Blood Res. 2017;52:69–71.
   PubMed Web of Science ®Google Scholar
• Roesmann A, Afify M, Panse J, et al. L-carnitine ameliorates L-asparaginase-induced acute liver toxicity in steatotic rat livers. Chemotherapy. 2013;59:167–175.
   PubMed Web of Science ®Google Scholar
• Al-Nawakil C, Willems L, Mauprivez C, et al. Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors. Leuk Lymphoma. 2014;55:1670–1674.
   PubMed Web of Science ®Google Scholar
• Alshiekh-Nasany R, Douer D. L-Carnitine for treatment of pegasparaginase-induced hepatotoxicity. Acta Haematol. 2016;135:208–210.
   PubMed Web of Science ®Google Scholar
• Lu G, Karur V, Herrington JD, et al. Successful treatment of pegaspargase-induced acute hepatotoxicity with vitamin B complex and L-carnitine. Proc (Bayl Univ Med Cent). 2016;29:46–47.
   PubMedGoogle Scholar
• Blackman A, Boutin A, Shimanovsky A, et al. Levocarnitine and vitamin B complex for the treatment of pegaspargase-induced hepatotoxicity: a case report and review of the literature. J Oncol Pharm Pract. 2017;Jan 1.
   PubMed Web of Science ®Google Scholar
• Sahoo S, Hart J. Histopathological features of L-asparaginase-induced liver disease. Semin Liver Dis. 2003;23:295–299.
   PubMed Web of Science ®Google Scholar
• Pratt CB, Johnson WW. Duration and severity of fatty metamorphosis of the liver following L-asparaginase therapy. Cancer. 1971;28:361–364.
   PubMed Web of Science ®Google Scholar
• Bilgir O, Calan M, Bilgir F, et al. An experience with plasma exchange treatment of acute lymphoblastic leukemia in a case with fulminant hepatitis related to L-asparaginase. Transfus Apher Sci. 2013;49:328–330.
   PubMed Web of Science ®Google Scholar
• Bodmer M, Sulz M, Stadlmann S, et al. Fatal liver failure in an adult patient with acute lymphoblastic leukemia following treatment with L-asparaginase. Digestion. 2006;74:28–32.
   PubMed Web of Science ®Google Scholar
• Okamura A, Nishimura M, Sanada Y, et al. L-Asparaginase-induced fulminating liver dysfunction. Int J Hematol. 2013;98:6–7.
   PubMed Web of Science ®Google Scholar
• Jenkins R, Perlin E. Severe hepatotoxicity from Escherichia coli L-asparaginase. J Natl Med Assoc. 1987;79:775.
   PubMed Web of Science ®Google Scholar
• Orgel E, Sposto R, Malvar J, et al. Impact on survival and toxicity by duration of weight extremes during treatment for pediatric acute lymphoblastic leukemia: a report from the Children’s Oncology Group. J Clin Oncol. 2014;32:1331–1337.
   PubMed Web of Science ®Google Scholar
• Schneider AL, Lazo M, Selvin E, et al. Racial differences in nonalcoholic fatty liver disease in the U.S. population. Obesity (Silver Spring). 2014;22:292–299.
   PubMed Web of Science ®Google Scholar
• Perez-Carreras M, Del Hoyo P, Martin MA, et al. Defective hepatic mitochondrial respiratory chain in patients with nonalcoholic steatohepatitis. Hepatology. 2003;38:999–1007.
   PubMed Web of Science ®Google Scholar
• Nikonorova IA, Al-Baghdadi RJT, Mirek ET, et al. Obesity challenges the hepatoprotective function of the integrated stress response to asparaginase exposure in mice. J Biol Chem. 2017;292:6786–6798.
   PubMed Web of Science ®Google Scholar
• Labbe G, Pessayre D, Fromenty B. Drug-induced liver injury through mitochondrial dysfunction: mechanisms and detection during preclinical safety studies. Fundam Clin Pharmacol. 2008;22:335–353.
   PubMed Web of Science ®Google Scholar
• Durden DL, Salazar AM, Distasio JA. Kinetic analysis of hepatotoxicity associated with antineoplastic asparaginases. Cancer Res. 1983;43:1602–1605.
   PubMed Web of Science ®Google Scholar
• Reinert RB, Oberle LM, Wek SA, et al. Role of glutamine depletion in directing tissue-specific nutrient stress responses to L-asparaginase. J Biol Chem. 2006;281:31222–31233.
   PubMed Web of Science ®Google Scholar
• Wu H, Liu Y, Pi D, et al. Asparagine attenuates hepatic injury caused by lipopolysaccharide in weaned piglets associated with modulation of Toll-like receptor 4 and nucleotide-binding oligomerisation domain protein signalling and their negative regulators. Br J Nutr. 2015;114:189–201.
   PubMed Web of Science ®Google Scholar
• Rebouche CJ, Paulson DJ. Carnitine metabolism and function in humans. Annu Rev Nutr. 1986;6:41–66.
   PubMed Web of Science ®Google Scholar
• Brinkman K, Vrouenraets S, Kauffmann R, et al. Treatment of nucleoside reverse transcriptase inhibitor-induced lactic acidosis. AIDS. 2000;1;14:2801–2802.
   Google Scholar
• Claessens YE, Cariou A, Chiche JD, et al. L-Carnitine as a treatment of life-threatening lactic acidosis induced by nucleoside analogues. AIDS. 2000;14:472–473.
   PubMed Web of Science ®Google Scholar
• Russell S. Carnitine as an antidote for acute valproate toxicity in children. Curr Opin Pediatr. 2007;19:206–210.
   PubMed Web of Science ®Google Scholar
• Perrott J, Murphy NG, Zed PJ. L-carnitine for acute valproic acid overdose: a systematic review of published cases. Ann Pharmacother. 2010;44:1287–1293.
   PubMed Web of Science ®Google Scholar
• Product monograph – Carnitor (levocarnitine) oral and injection. Gaithersburg (MD): Sigma-Tau Pharmaceuticals Inc.; 2015 [updated 2015 April; 2017 May 12]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/018948s026,019257s012,020182s013lbl.pdf
   Google Scholar
• Hong ES, Kim EK, Kang SM, et al. Effect of carnitine-orotate complex on glucose metabolism and fatty liver: a double-blind, placebo-controlled study. J Gastroenterol Hepatol. 2014;29:1449–1457.
   PubMed Web of Science ®Google Scholar
• Malaguarnera M, Gargante MP, Russo C, et al. L-carnitine supplementation to diet: a new tool in treatment of nonalcoholic steatohepatitis–a randomized and controlled clinical trial. Am J Gastroenterol. 2010;105:1338–1345.
   PubMed Web of Science ®Google Scholar
• Jun DW, Kim BI, Cho YK, et al. Efficacy and safety of entecavir plus carnitine complex (GODEX®) compared to entecavir monotherapy in patient with ALT elevated chronic hepatitis B: randomized, multicenter open-label trials. The GOAL study. Clin Mol Hepatol. 2013;19:165–172.
   PubMedGoogle Scholar
• Avramis VI, Sencer S, Periclou AP, et al. A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study. Blood. 2002;99:1986–1994.
   PubMed Web of Science ®Google Scholar
• Dinndorf PA, Gootenberg J, Cohen MH, et al. FDA drug approval summary: pegaspargase (oncaspar) for the first-line treatment of children with acute lymphoblastic leukemia (ALL). Oncologist. 2007;12:991–998.
   PubMed Web of Science ®Google Scholar
• Duval M, Suciu S, Ferster A, et al. Comparison of Escherichia coli-asparaginase with Erwinia-asparaginase in the treatment of childhood lymphoid malignancies: results of a randomized European Organisation for Research and Treatment of Cancer-Children’s Leukemia Group phase 3 trial. Blood. 2002;99:2734–2739.
   PubMed Web of Science ®Google Scholar
• Sayed-Ahmed MM, Shaarawy S, Shouman SA, et al. Reversal of doxorubicin-induced cardiac metabolic damage by L-carnitine. Pharmacol Res. 1999;39:289–295.
   PubMed Web of Science ®Google Scholar
• Delaney CE, Hopkins SP, Addison CL. Supplementa-tion with l-carnitine does not reduce the efficacy of epirubicin treatment in breast cancer cells. Cancer Lett. 2007;252:195–207.
   PubMed Web of Science ®Google Scholar
• Niang M, Melka M, Stoklasova A, et al. Evaluation of the antineoplastic activity of mitoxantrone-L-carnitine combination therapy on an experimental solid form of ehrlich tumour in mice. Pharmacol Res. 2006;54:447–451.
   PubMed Web of Science ®Google Scholar